|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400094535 |
|
最近更新日期: Date of Last Refreshed on: |
2024-12-24 14:29:32 |
|
注册时间: Date of Registration: |
2024-12-24 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
玫瑰痤疮与肠道微生物关系研究 |
|
Public title: |
Relationship between rosacea and intestinal microbiota |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
玫瑰痤疮与肠道微生物关系研究 |
|
Scientific title: |
Relationship between rosacea and intestinal microbiota |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
王莲 |
研究负责人: |
蒋献 |
|
Applicant: |
Lian Wang |
Study leader: |
Xian Jiang |
|
申请注册联系人电话: Applicant telephone: |
+86 199 8320 8259 |
研究负责人电话: Study leader's telephone: |
+86 189 8060 1693 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
2753269728@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
jiangxian@scu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
四川大学华西医院皮肤性病科 |
研究负责人通讯地址: |
四川大学华西医院皮肤性病科 |
|
Applicant address: |
Department of Dermatology, West China Hospital, Sichuan University |
Study leader's address: |
Department of Dermatology, West China Hospital, Sichuan University, |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
四川大学华西医院 |
||
|
Applicant's institution: |
West China Hospital of Sichuan University |
||
|
研究负责人所在单位: |
四川大学华西医院 |
||
|
Affiliation of the Leader: |
West China Hospital of Sichuan University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2021年审(717)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
四川大学华西医院生物医学伦理审查委员会批件 |
||
|
Name of the ethic committee: |
Ethics Committee on Biomedical Research, West China Hospital of Sichuan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2021-08-06 00:00:00 |
||
|
伦理委员会联系人: |
李娜 |
||
|
Contact Name of the ethic committee: |
Na Li |
||
|
伦理委员会联系地址: |
四川大学华西医院 |
||
|
Contact Address of the ethic committee: |
West China Hospital of Sichuan University |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 28 8542 2158 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
四川大学华西医院 |
||||||||||||||||||||||
|
Primary sponsor: |
West China Hospital of Sichuan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
四川省成都市国学巷 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Guoxue Lane, Chengdu City, Sichuan Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
四川大学华西医院院-企合作临床研究创新项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Hospital-enterprise cooperative clinical research innovation Project of West China Hospital of Sichuan University |
||||||||||||||||||||||
|
Target disease: |
Rosacea |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
1.建立玫瑰痤疮患者肠道菌群分布特征及小分子代谢物组成模型。 2.探讨常见影响肠道菌群的因素(饮食、生活习惯)对菌群分布模型及小代谢物组成的作用,进而揭示其对玫瑰痤疮疾病严重程度的影响。 3.研究双歧杆菌三联活菌对玫瑰痤疮患者临床及肠道微生物的影响。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. To establish the intestinal microbiota distribution characteristics and small molecule metabolite composition model of rosacea patients. 2. To explore the effects of common factors (diet and lifestyle) affecting intestinal microbiota on the distribution model of microbiota and the composition of small metabolites, so as to reveal their influence on the severity of rosacea disease. 3. To study the effects of bifidobacterium triple viable bacteria on clinical and intestinal microorganisms in patients with rosacea. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.诊断符合玫瑰痤疮(根据 2017 年全球 ROSacea 共识,存在以下任意一条即可诊断: 面中部固定红斑,伴有周期性加重的特征性模式;鼻赘改变;存在以下 2-3 条可诊 断:潮红;丘疹和脓疱;毛细血管扩张;眼部症状)。 2.年龄 18 岁至 60 岁。 3.无严重的器质性疾病。 4.患者同意参加本临床试验并签署书面知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Diagnosis consistent with rosacea (according to the 2017 Global ROSacea Consensus, diagnosis can be made if any of the following are present: fixed erythema in the middle of the face, with a characteristic pattern of periodic exacerbations; rhinophyma changes; The following 2 to 3 are diagnostic Broken: flushed; papules and pustules; telangiectasia; ocular symptoms). 2. Age 18 to 60 years. 3. No serious organic diseases. 4. Patient agrees to participate in this clinical trial and signs written informed consent. |
||||||||||||||||||||||
|
排除标准: |
1.年龄小于 18 岁或大于 60 岁。 2.有精神性疾病及认知障碍者。 3.近4周有服用干扰肠道菌群的药物或制剂(如抗生素、益生菌等) |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Age less than 18 years or older than 60 years. 2. Those with mental illness and cognitive impairment. 3. Have taken drugs or preparations that interfere with the intestinal flora (such as antibiotics, probiotics, etc.) in the past 4 weeks |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-02-01 00:00:00至 To 2024-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2023-04-04 00:00:00 至 To 2024-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
随机数字表 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Random number table |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
双盲,对研究参与者和研究者设盲 |
|
Blinding: |
Double-blind, blinding the study participants and investigators |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究结束后,通过ResMan(www.medresman.org.cn)方式共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After the end of the study, it was shared by ResMan (www.medresman.org.cn). |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic Data Capture |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |